The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment

被引:10
作者
Bae, Bong Kyung [1 ]
Park, Hee Chul [1 ]
Yoo, Gyu Sang [1 ]
Choi, Moon Seok [2 ]
Oh, Joo Hyun [2 ]
Yu, Jeong Il [1 ]
机构
[1] Sungkyunkwan Univ, Dept Radiat Oncol, Samsung Med Ctr, Sch Med, Seoul 06351, South Korea
[2] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul 06351, South Korea
基金
新加坡国家研究基金会;
关键词
hepatocellular carcinoma; intrahepatic recurrence; systemic inflammatory marker; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; lymphocyte-to-monocyte ratio; VS. RADIOFREQUENCY ABLATION; LYMPHOCYTE RATIO; RISK-FACTORS; TRANSARTERIAL CHEMOEMBOLIZATION; HEPATECTOMY; RESECTION; NEUTROPHIL; SURVIVAL; CANCER; INVASION;
D O I
10.3390/cancers14092081
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary This retrospective study using the prospectively collected registry data of newly diagnosed, previously untreated hepatocellular carcinoma (HCC) evaluates the significance of systemic inflammatory markers (SIMs) to intrahepatic recurrence (IHR) after curative treatment. Out of 4076 patients who met the inclusion criteria, 52.6% experienced IHR. SIMs, including pre-treatment platelet-to-lymphocyte ratio (PLR), post-treatment changes of neutrophil-to-lymphocyte ratio PLR, and lymphocyte-to-monocyte ratio were significantly associated with the prognosis of early-stage HCC patients who received initial curative treatment. The prognostic significances of SIMs were consistent for IHR-free survival, early and late IHR, and overall survival. Systemic inflammatory markers (SIMs) are known to be associated with carcinogenesis and prognosis of hepatocellular carcinoma (HCC). We evaluated the significance of SIMs in intrahepatic recurrence (IHR) of early-stage HCC after curative treatment. This study was performed using prospectively collected registry data of newly diagnosed, previously untreated HCC between 2005 and 2017 at a single institution. Inclusion criteria were patients with Barcelona Clinic Liver Cancer stage 0 or A, who underwent curative treatment. Pre-treatment and post-treatment values of platelet, neutrophil, lymphocyte, monocyte, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) were analyzed with previously well-known risk factors of HCC to identify factors associated with IHR-free survival (IHRFS), early IHR, and late IHR. Of 4076 patients, 2142 patients (52.6%) experienced IHR, with early IHR in 1018 patients (25.0%) and late IHR in 1124 patients (27.6%). Pre-treatment platelet count and PLR and post-treatment worsening of NLR, PLR, and LMR were independently associated with IHRFS. Pre-treatment platelet count and post-treatment worsening of NLR, PLR, and LMR were significantly related to both early and late IHR. Pre-treatment values and post-treatment changes in SIMs were significant factors of IHR in early-stage HCC, independent of previously well-known risk factors of HCC.
引用
收藏
页数:14
相关论文
共 47 条
[1]   Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study [J].
Bholee, A. K. ;
Peng, K. ;
Zhou, Z. ;
Chen, J. ;
Xu, L. ;
Zhang, Y. ;
Chen, M. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (07) :844-852
[2]   From LI-RADS Classification to HCC Pathology: A Retrospective Single-Institution Analysis of Clinico-Pathological Features Affecting Oncological Outcomes after Curative Surgery [J].
Centonze, Leonardo ;
De Carlis, Riccardo ;
Vella, Ivan ;
Carbonaro, Luca ;
Incarbone, Niccolo ;
Palmieri, Livia ;
Sgrazzutti, Cristiano ;
Ficarelli, Alberto ;
Valsecchi, Maria Grazia ;
Dello Iacono, Umberto ;
Lauterio, Andrea ;
Bernasconi, Davide ;
Vanzulli, Angelo ;
De Carlis, Luciano .
DIAGNOSTICS, 2022, 12 (01)
[3]   Prognostic factors for hepatocellular carcinoma recurrence [J].
Colecchia, Antonio ;
Schiumerini, Ramona ;
Cucchetti, Alessandro ;
Cescon, Matteo ;
Taddia, Martina ;
Marasco, Giovanni ;
Festi, Davide .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (20) :5935-5950
[4]   A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma [J].
Dhir, Mashaal ;
Melin, Alyson A. ;
Douaiher, Jeffrey ;
Lin, Chi ;
Zhen, Weining ;
Hussain, Shahid M. ;
Geschwind, Jean-Francois H. ;
Doyle, Maria B. Majella ;
Abou-Alfa, Ghassan K. ;
Are, Chandrakanth .
ANNALS OF SURGERY, 2016, 263 (06) :1112-1125
[5]   Cancer-related inflammation and treatment effectiveness [J].
Diakos, Connie I. ;
Charles, Kellie A. ;
McMillan, Donald C. ;
Clarke, Stephen J. .
LANCET ONCOLOGY, 2014, 15 (11) :E493-E503
[6]   Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms [J].
Elinav, Eran ;
Nowarski, Roni ;
Thaiss, Christoph A. ;
Hu, Bo ;
Jin, Chengcheng ;
Flavell, Richard A. .
NATURE REVIEWS CANCER, 2013, 13 (11) :759-771
[7]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[8]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[9]   The diagnosis and treatment of hepatocellular carcinoma [J].
Hartke, Justin ;
Johnson, Matthew ;
Ghabril, Marwan .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2017, 34 (02) :153-159
[10]  
Hayashi M, 2011, AM SURGEON, V77, P572